By Nanotechnology Characterization Laboratory (NCL)
The NCL covers a multitude of nanoparticle platforms and biocompatibility data, characterization techniques, and their technical nuances. This knowledge is leveraged to provide sponsor-funded research and development for applications beyond the Assay Cascade’s constraints. It is carried out through a contractor, Cooperative Research and Development Agreement (cCRADA). While the Assay Cascade is restricted to characterization of oncology-based nanomedicines, cCRADA collaborations are not. cCRADA projects cover a broad range of research, including characterization of oncology or non-oncology nanomaterials, mechanistic studies, nanotech formulation projects, and more. NCL collaborates with each sponsor to create a tailored, highly customized research plan for each cCRADA project. cCRADA candidate projects are considered on a case-by-case basis throughout the year. We take several criteria into consideration, including optimal use of NCL’s capabilities and resources and alignment with NCL and NCI’s research interests. We also weigh a project's potential impact to improve nanomedicine research and development. Interested parties can email the NCL (ncl@mail.nih.gov) to discuss their project needs. For approved projects, work is initiated through a cCRADA with Leidos Biomedical Research, Inc., the operations and technical support contractor for the Frederick National Lab.
